A novel CAR T-cell therapy, developed by UCL researchers and designed to target cancer cells more quickly and cause fewer side effects, has shown very promising results for children with previously incurable acute lymphoblastic leukemia (ALL).
The CARPALL trial, led by Professor Persis Amrolia and Dr. Sara Ghorashian at Great Ormond Street Hospital (GOSH) and the UCL Great Ormond Street Institute of Child Health (UCL GOS ICH), tested a new kind of CAR T-cell therapy in children and young adults with relapsed ALL.
In CAR T therapy, immune cells (T-cells) are engineered to contain a molecule called a chimeric antigen receptor (CAR) on their surface which can specifically recognize cancerous cells. In this approach, the patient’s own T cells are genetically modified to contain a new type of CAR molecule known as CAT-19, which was developed in Dr. Martin Pule’s laboratory at the UCL Cancer Institute.
The modified CAR T-cells were used to treat 14 patients with relapsed ALL at GOSH, Manchester Children’s Hospital and University College Hospital, London.
Published in Nature Medicine today, the results show that after receiving the CAR T treatment, 12 out of 14 patients with otherwise incurable ALL cleared their disease after three months and five patients remain leukemia-free. Patients also experienced less of a harmful side effect known as cytokine release syndrome (CRS).
ALL affects around 400 children a year in the UK and, while most patients are curable with standard treatments like chemotherapy and transplant, in some patients the disease comes back (relapses) despite maximal treatment.
CAR T-cells have shown great promise for relapsed ALL—the most common cause of cancer death in children in the UK.
The study, which was funded by Great Ormond Street Hospital Children’s Charity and Children with Cancer UK, opened in June 2016, enabling UK patients to have access to this ground-breaking new treatment before a commercial CAR-T cell therapy, Kymriah, became available on the NHS.
In the study laboratory experiments showed that, compared to other CAR T therapies, the CAT-19 CAR T cells were able to grow better after encountering leukemia cells.
In patients, high numbers of the CAT-19 CAR T-cells were still present in the blood after the cancer had been cleared, enabling the body to keep fighting against the leukemia even years after treatment.
Patients receiving CAR T therapies often experience CRS as the immune system becomes overactive attempting to fight the cancer cells. It can cause patients to be admitted to intensive care and can lead to death.
To avoid this, the CAR T therapy used in the CARPALL trial has been designed so that it interacts with its target on the surface of cancer cells more rapidly than other similar therapies.
This means that while CAR T-cells can still kill leukemia cells efficiently, the cells cause less activation of the immune system and therefore fewer dangerous side effects.
No patients who received the new therapy developed severe CRS suggesting that this therapy is safer than other CAR T-cell therapies, though this will need to be confirmed in larger studies.
Professor Amrolia, study Chief Investigator and National Institute for Health Research (NIHR) Research Professor at UCL GOS ICH, said: “CAR T therapy is a fantastic example of using the power of the immune system to specifically target cancer cells.
While it doesn’t work for everyone, it can offer hope for those children who have run out of all other options.
“We’re just at the beginning of this new treatment and over the next few years I hope we can refine it further to make it safer and more effective.
The side effects of CAR T therapies can be severe, so we hope that this new technology can reduce the risk for patients.”
Dr. Martin Pule (UCL Cancer Institute) said: “Our preclinical studies of this new therapy suggested that CAT-19 CAR T-cells would engraft better and it is gratifying to see this replicated in patients.”
Co-author Dr. Sara Ghorashian, UCL GOS ICH and GOSH, said: “
The safety profile emerging from this pediatric study is encouraging. CAT-19 was well-tolerated and we did not see severe cytokine release syndrome or neurotoxicity seen in other ALL programs.
“It is very promising to see these strong remission rates and excellent CAR T cell expansion and persistence, which gives us hope that CAT-19 could improve outcomes for these patients.”
The CARPALL study was also funded by the JP Moulton Foundation and the work was underpinned by the NIHR Biomedical Research Centres at GOSH and University College London Hospitals NHS Foundation Trust (UCLH).
The study is part of UCL’s pioneering CAR T-cell program which currently has nine Phase I studies, including a related study looking at the use of the same therapy to treat adult patients. Other research in the center aims to extend CAR T cell therapy to other cancers.
General Information About Childhood Acute Lymphoblastic Leukemia (ALL)
Cancer in children and adolescents is rare, although the overall incidence of childhood cancer, including ALL, has been slowly increasing since 1975. Dramatic improvements in survival have been achieved in children and adolescents with cancer.[1–3]
Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[1–3] For ALL, the 5-year survival rate has increased over the same time from 60% to approximately 90% for children younger than 15 years and from 28% to more than 75% for adolescents aged 15 to 19 years.
Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment. (Refer to the PDQ summary on Late Effects of Treatment for Childhood Cancer for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.)
In the United States, ALL occurs at an annual rate of approximately 41 cases per 1 million people aged 0 to 14 years and approximately 17 cases per 1 million people aged 15 to 19 years.
There are approximately 3,100 children and adolescents younger than 20 years diagnosed with ALL each year in the United States. Since 1975, there has been a gradual increase in the incidence of ALL.[4,6]
The incidence of ALL among children aged 2 to 3 years is approximately fourfold greater than that for infants and is likewise fourfold to fivefold greater than that for children aged 10 years and older.[2,3]
The incidence of ALL appears to be highest in Hispanic children (43 cases per 1 million).[2,3,7,8] The incidence is substantially higher in white children than in black children, with a nearly threefold higher incidence of ALL from age 2 to 3 years in white children than in black children.[2,3,7]
Childhood ALL originates in the T and B lymphoblasts in the bone marrow (refer to Figure 1).
arrow involvement of acute leukemia as seen by light microscopy is defined as follows:
- M1: Fewer than 5% blast cells.
- M2: 5% to 25% blast cells.
- M3: Greater than 25% blast cells.
Almost all patients with ALL present with an M3 marrow.
More information: Sara Ghorashian et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR, Nature Medicine (2019). DOI: 10.1038/s41591-019-0549-5
Journal information: Nature Medicine
Provided by University College London